-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $20

Benzinga·11/16/2026 13:36:29
Listen to the news
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $17 to $20.